CT-P13 SC (Infliximab)
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Crohn's Disease
Conditions
Crohn's Disease
Trial Timeline
Oct 28, 2019 → Aug 22, 2023
NCT ID
NCT03945019About CT-P13 SC (Infliximab)
CT-P13 SC (Infliximab) is a phase 3 stage product being developed by Celltrion for Crohn's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03945019. Target conditions include Crohn's Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04205643 | Phase 3 | Completed |
| NCT03945019 | Phase 3 | Completed |
Competing Products
20 competing products in Crohn's Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CT-P13 + Remicade | Celltrion | Phase 3 | 77 |
| CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 | Celltrion | Phase 1 | 33 |
| CP-461 | Astellas Pharma | Phase 2 | 52 |
| E6011 2 mg/kg + E6011 5 mg/kg + E6011 10 mg/kg + E6011 15 mg/kg | Eisai | Phase 1/2 | 41 |
| E6011 + Placebo | Eisai | Phase 2 | 52 |
| E6011 + Placebo | Eisai | Phase 1 | 33 |
| adalimumab + adalimumab + placebo | Eisai | Phase 2/3 | 65 |
| adalimumab | Eisai | Phase 2/3 | 65 |
| Mirikizumab + Mirikizumab + Ustekinumab + Ustekinumab + Placebo + Placebo | Eli Lilly | Phase 3 | 77 |
| Mirikizumab | Eli Lilly | Phase 3 | 77 |
| Mirikizumab + Mirikizumab + Tirzepatide + Placebo | Eli Lilly | Phase 3 | 77 |
| Mirikizumab + Placebo | Eli Lilly | Phase 2 | 52 |
| Mirikizumab | Eli Lilly | Phase 3 | 77 |
| Matching Placebo for Upadacitinib + Upadacitinib | AbbVie | Phase 3 | 77 |
| Adalimumab + Placebo | AbbVie | Phase 3 | 77 |
| Upadacitinib + Placebo for Upadacitinib | AbbVie | Phase 3 | 77 |
| Placebo + ABT-494 | AbbVie | Phase 2 | 52 |
| ABT-494 | AbbVie | Phase 2 | 52 |
| Risankizumab + Comparator | AbbVie | Pre-clinical | 23 |
| placebo for risankizumab + risankizumab IV + risankizumab SC | AbbVie | Phase 3 | 77 |
Other Products from Celltrion
Azathioprine + PlaceboApproved
85
Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)Approved
85
Infliximab + Infliximab + InfliximabApproved
85
Pioglitazone + Alogliptin + Alogliptin + Metformin + DapagliflozinApproved
85
Pioglitazone 15 MG [Actos] + Empagliflozin 10 MG [Jardiance] + Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]Approved
85